FiercePharma  Apr 21  Comment 
The third time wasn’t the charm for Takeda in its attempts to swallow Shire—but the fourth time might be. On Friday, the Dublin drugmaker said Japan’s largest pharma offered £47 per share, almost half of that in cash, or about £44 billion...
CNNMoney.com  Apr 20  Comment 
Prospects of a bidding war drove up the stock of biotech firm Shire this week. Now Takeda has the field to itself and has tabled a fourth, slightly sweeter proposal.
Motley Fool  Apr 20  Comment 
Takeda's made three offers to acquire Shire in the past month. Now a new bidder is emerging for the U.K. biopharma.
CNNMoney.com  Apr 19  Comment 
Read full story for latest details.
GenEng News  Apr 19  Comment 
Shire said today its board has rejected at least two takeover proposals by Takeda Pharmaceutical, but both companies have confirmed that they remain in talks about a possible acquisition. Shire’s board turned down Takeda’s initial...
Wall Street Journal  Apr 19  Comment 
Wall Street Journal  Apr 16  Comment 
Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover.
FiercePharma  Apr 13  Comment 
Novartis is facing allegations in China that it laundered doctor kickbacks through fake academic events, Samsung Bioepis has pushed back the U.S. launch of its Humira biosimilar by years, Takeda is seeking billions of dollars in loans to finance...
FiercePharma  Apr 12  Comment 
The Shire bid Takeda’s been discussing is getting real. The Japanese drugmaker is gauging lender interest in financing a bid that tops $40 billion, Reuters’ sources say. And Takeda will need some serious money; it's looking for tens of...
Motley Fool  Apr 10  Comment 
Takeda could struggle to finance this megadeal.


No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki